EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti‐seizure medication

Daniel L Kenney-Jung, Josue E Collazo-Lopez, Dante J Rogers, Ryan Shanley, Abigail L Zatkalik, Ashley E Whitmarsh, Amy E Roberts, Martin Zenker iD, Elizabeth I Pierpont iD

American Journal of Medical Genetics Part A · 2024-02 · 194 (2) · 301-310

DOI: 10.1002/ajmg.a.63428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 12.10.2023. Verfasst von Daniel L Kenney-Jung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Duke University, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Epilepsy, Drug-Related Side Effects and Adverse Reactions, Ectodermal Dysplasia, Failure to Thrive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NINDS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment‐resistant epilepsy is among the most serious complications of cardiofaciocutaneous syndrome (CFCS), a rare disorder caused by germline variants in the RAS‐MAPK signaling pathway. This study analyzed the clinical characteristics of epilepsy and response to anti‐seizure medications (ASMs) in a multinational CFCS cohort. A caregiver survey provided data regarding seizure history, use of ASMs and other treatment approaches, adverse effects, caregiver perception of treatment response, and neurological disease burden impact among individuals with CFCS. Results from 138 survey responses were quantitatively analyzed in conjunction with molecular genetic results and neurological records. The disease burden impact of CFCS was higher among individuals with epilepsy ( n = 74/138), especially those with more severe seizure presentation. Oxcarbazepine, a sodium‐channel blocker, had the best seizure control profile with relatively infrequent adverse effects. The most commonly prescribed ASM, levetiracetam, demonstrated comparatively poor seizure control. ASM efficacy was generally similar for individuals with BRAF and MAP2K1 gene variants. The high proportion of patients with CFCS who experienced poor seizure control despite use of multiple ASMs highlights a substantial unmet treatment need. Prospective study of ASM efficacy and clinical trials of therapies to attenuate RAS‐MAPK signaling may improve avenues for clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyDrug-Related Side Effects and Adverse ReactionsEctodermal DysplasiaFailure to ThriveHeart Defects, CongenitalFaciesHumansProspective StudiesLevetiracetamSeizuresAnticonvulsants

Stichwörter der Autor:innen

BRAFMAP2K1RASopathiesseizurestreatment

Substanzen

LevetiracetamAnticonvulsants

Autor:innen und Institutionen

  • Department of Pediatrics, Duke University, Durham, North Carolina, USA.
  • Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
  • Ponce Health Sciences University, Ponce, Puerto Rico, USA.
  • Biostatistical Design and Analysis Center, Clinical and Translational Science Institute, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
  • Department of Cardiology and Department of Pediatrics, Division of Genetics and Genomics, Boston Childrens Hospital, Boston, Massachusetts, USA.
  • Institute of Human Genetics, University Hospital, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

ORCID-Profile: Martin Zenker, Elizabeth I Pierpont

Förderung

  • NCATS NIH HHS
  • NINDS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Kenney-Jung, D. L., Collazo-Lopez, J. E., Rogers, D. J., Shanley, R., Zatkalik, A. L., Whitmarsh, A. E., Roberts, A. E., Zenker, M., & Pierpont, E. I. (2024). Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti‐seizure medication. American Journal of Medical Genetics Part A, 194(2), 301-310. https://doi.org/10.1002/ajmg.a.63428

Vancouver

Kenney-Jung DL, Collazo-Lopez JE, Rogers DJ, Shanley R, Zatkalik AL, Whitmarsh AE, et al. Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti‐seizure medication. American Journal of Medical Genetics Part A. 2024;194(2):301-310. doi:10.1002/ajmg.a.63428

BibTeX
@article{KenneyJung2024,
  author = {Kenney-Jung, Daniel L and Collazo-Lopez, Josue E and Rogers, Dante J and Shanley, Ryan and Zatkalik, Abigail L and Whitmarsh, Ashley E and Roberts, Amy E and Zenker, Martin and Pierpont, Elizabeth I},
  title = {Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti‐seizure medication},
  journal = {American Journal of Medical Genetics Part A},
  year = {2024},
  volume = {194},
  number = {2},
  pages = {301--310},
  doi = {10.1002/ajmg.a.63428}
}
Kostenlos starten →